Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

被引：2

作者：

Pennesi, Edoardo ^{[1
,2
]}

Brivio, Erica ^{[1
,2
]}

Pelletier, Kathleen B. ^{[3
]}

Chen, Ying ^{[4
]}

Huitema, Alwin D. R. ^{[2
,5
,6
]}

Jiang, Yilin ^{[2
]}

Ammerlaan, Anneke C. J. ^{[1
,2
]}

Sleight, Barbara ^{[3
]}

Locatelli, Franco ^{[7
]}

Van der Sluis, Inge M. ^{[2
]}

Rossig, Claudia ^{[8
]}

Chen-Santel, Christiane ^{[9
]}

Bielorai, Bella ^{[10
]}

Petit, Arnaud ^{[11
]}

Stary, Jan ^{[12
]}

Sramkova, Lucie ^{[12
]}

de Heredia Rubio, Cristina Diaz ^{[13
]}

Rives, Susana ^{[14
]}

O'Marcaigh, Aengus ^{[15
]}

Rizzari, Carmelo ^{[16
]}

Engstler, Gernot ^{[17
]}

Nysom, Karsten ^{[18
]}

Rubio-San-Simon, Alba ^{[19
]}

Sirvent, Francisco J. Bautista ^{[2
]}

Bruno, Benedicte ^{[20
]}

Bertrand, Yives ^{[21
]}

Brethon, Benoit ^{[22
]}

Rialland, Fanny ^{[23
]}

Plat, Genevieve ^{[24
]}

Dirksen, Uta ^{[25
]}

Garrett, May ^{[26
]}

Zwaan, Christian M. ^{[1
,2
]}

机构：

[1] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol, Rotterdam, Netherlands

[2] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

[3] Pfizer Inc, Groton, CT 06340 USA

[4] Pfizer Inc, La Jolla, CA USA

[5] Univ Med Ctr Utrecht, Utrecht, Netherlands

[6] Netherlands Canc Inst, Amsterdam, Netherlands

[7] Univ Cattolica Sacro Cuore, IRCCS Osped Pediat Bambino Gesu, Rome, Italy

[8] Univ Childrens Hosp Munster, Dept Pediat Hematol & Oncol, Munster, Germany

[9] Rostock Med Ctr, Rostock, Germany

[10] Sheba Med Ctr, Div Pediat Hematol & Oncol, Ramat Gan, Israel

[11] Sorbonne Univ, Trousseau Hosp, Hop Armand Trousseau, AP HP,Pediat Hematol & Oncol Dept, Paris, France

[12] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic

[13] Hosp Univ Vall dHebron, Div Pediat Hematol & Oncol, Barcelona, Spain

[14] Hosp St Joan Deu Barcelona, Dept Pediat Hematol & Oncol, Barcelona, Spain

[15] Hosp Sick Children, Dublin, Ireland

[16] Univ Milano Bicocca, San Gerardo Hosp, MBBM Fdn, Pediat Hematol Oncol Unit, Monza, Italy

[17] Med Univ Vienna, St Anna Childrens Hosp, Vienna, Austria

[18] Rigshosp, Dept Paediat & Adolescent Med, Copenhagen, Denmark

[19] Hosp Nino Jesus, Dept Pediat Oncol & Hematol, Madrid, Spain

[20] CHRU Lille, Hop Jeanne de Flandre, Pediat Hematol, Lille, France

[21] Claude Bernard Univ, Inst Pediat Hematol & Oncol, Civil Hosp Lyon, Lyon, France

[22] Univ Paris, Robert Debre Hosp, AP HP, Dept Pediat Hematol & Immunol, Paris, France

[23] Nantes Univ Hosp, Serv Oncohematol Pediat, Hop Mere Enfant, Nantes, France

[24] CHU Toulouse, Hop Enfants, Serv Hematol Immunol Oncol, Toulouse, France

[25] Essen Univ Hosp, West German Canc Ctr, German Canc Consortium DKTK, Pediat 3, Essen, Germany

[26] Pfizer Oncol, La Jolla, CA USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165954

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

605

引用

页码：8845 / 8847

页数：3

共 50 条

[21] Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
Jabbour, Elias
Goekbuget, Nicola
Advani, Anjali
Stelljes, Matthias
Stock, Wendy
Liedtke, Michaela
Martinelli, Giovanni
O'Brien, Susan
Wang, Tao
Laird, A. Douglas
Vandendries, Erik
Neuhof, Alexander
Nguyen, Kevin
Dakappagari, Naveen
DeAngelo, Daniel J.
Kantarjian, Hagop
LEUKEMIA RESEARCH, 2020, 88
[22] Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.
Jabbour, Elias
Advani, Anjali S.
Stelljes, Matthias
Stock, Wendy
Liedtke, Michaela
Gokbuget, Nicola
Martinelli, Giovanni
O'Brien, Susan Mary
Wang, Kongming
Wang, Tao
Paccagnella, M. Luisa
Sleight, Barbara
Vandendries, Erik
DeAngelo, Daniel J.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database
Jabbour, Elias
Stelljes, Matthias
Advani, Anjali S.
DeAngelo, Daniel J.
Goekbuget, Nicola
Marks, David I.
Stock, Wendy
O'Brien, Susan
Cassaday, Ryan D.
Wang, Tao
Neuhof, Alexander
Vandendries, Erik
Kantarjian, Hagop
LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 2012 - 2015
[24] A phase II study of single-agent gemtuzumab ozogamicin in relapsed/refractory pediatric acute myeloid leukemia (AML).
Zwaan, CM
Reinhardt, D
Zimmermann, M
Creutzig, U
Kaspers, GJL
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 806S - 806S
[25] EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN OLDER PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ENROLLED IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL
Jabbour, E. J.
Advani, A. S.
Stelljes, M.
Stock, W.
Liedtke, M.
Goekbuget, N.
Martinelli, G.
O'Brien, S.
Wang, K.
Wang, T.
Paccagnella, M. L.
Sleight, B.
Vandendries, E.
DeAngelo, D. J.
Kantarjian, H. M.
HAEMATOLOGICA, 2016, 101 : 32 - 32
[26] Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial
Zhao, Yaqi
Laird, A. Douglas
Roberts, Kathryn
Yafawi, Rolla
Kantarjian, Hagop
DeAngelo, Daniel J.
Stelljes, Matthias
Liedtke, Michaela
Stock, Wendy
Gokbuget, Nicola
O'Brien, Susan
Jabbour, Elias
Cassaday, Ryan D.
Loyd, Melanie R.
Olsen, Scott
Neale, Geoffrey
Liu, Xueli
Vandendries, Erik
Mullighan, Charles G.
Advani, Anjali
CANCER RESEARCH, 2022, 82 (12)
[27] Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level
Kantarjian, Hagop M.
Stock, Wendy
Cassaday, Ryan D.
DeAngelo, Daniel J.
Jabbour, Elias J.
O'Brien, Susan M.
Stelljes, Matthias
Wang, Tao
Paccagnella, Luisa
Nguyen, Kevin
Sleight, Barbara
Vandendries, Erik
Laird, A. Douglas
Advani, Anjali S.
BLOOD, 2017, 130
[28] Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Sasaki, Koji
Jabbour, Elias J.
O'Brien, Susan M.
Ravandi, Farhad
Thomas, Deborah A.
Kadia, Tapan M.
Garcia-Manero, Guillermo
Burger, Jan A.
Pemmaraju, Naveen
Alvarado, Yesid
Daver, Naval G.
Jain, Nitin
Konopleva, Marina
Champlin, Richard E.
Khouri, Issa F.
Kebriaei, Partow
Marin, David
DiNardo, Courtney D.
Estrov, Zeev
Takahashi, Koichi
Short, Nicholas J.
Khouri, Maria R.
Jacob, Jovitta
Garris, Rebecca
Cortes, Jorge E.
Kantarjian, Hagop M.
BLOOD, 2016, 128 (22)
[29] Inotuzumab ozogamicin (InO) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) in the global phase 3 randomized controlled ino-vate trial: efficacy and safety by age and prior therapy
Stelljes, M.
Kreuzer, K. -A
Deangelo, D. J.
Advani, A. S.
Goekbuget, N.
Liedtke, M.
Stock, W.
Martinelli, G.
O'Brien, S.
Wang, K.
Wang, T.
Paccagnella, M. L.
Sleight, B.
Vandendries, E.
Jabbour, E. J.
Kantarjian, H. M.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 201 - 202
[30] Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial
Marks, David I.
DeAngelo, Daniel J.
Stelljes, Matthias
Liedtke, Michaela
Stock, Wendy
Gokbuget, Nicola
O'Brien, Susan
Jabbour, Elias
Merchant, Akil
Wang, Tao
Vandendries, Eric
Neuhof, Alexander
Advani, Anjali
Kantarjian, Hagop
BONE MARROW TRANSPLANTATION, 2019, 54 : 149 - 151

← 1 2 3 4 5 →